She Gave Her Mother a Counterfeit Drug

In late 2022, Bhinnata Piya, a 36-year-old Nepali-American, obtained Keytruda for her mother through a medical tourism broker in India. Her mother, Sita Gurung, received the drug for two months with no effect. On February 9, 2023, after two and a half years of grueling treatment, she died at home.

A year later, Piya learned the broker who sold them the medication had been arrested by New Delhi police. According to police records, he allegedly filled vials labeled as Keytruda and other expensive oncology drugs with antifungal medicine. Piya had believed she was giving her mother real medicine. That belief had now collapsed.

This is not an isolated tragedy. According to an investigation by the International Consortium of Investigative Journalists (ICIJ), counterfeit versions of Keytruda—the world's bestselling cancer drug—have been widely distributed to patients and even medical institutions across the globe.

Why Keytruda?

Keytruda (pembrolizumab), developed by Merck, is a PD-1 immune checkpoint inhibitor approved for a wide range of cancers including lung cancer, melanoma, and esophageal cancer. Its annual revenue exceeded $25 billion in 2023, making it the single best-selling drug in the world.

The price is staggering—thousands of dollars per dose, tens of thousands for a full treatment course. Patients in countries with limited insurance coverage turn to informal channels: hospital middlemen, medical tourism brokers, and online marketplaces. Counterfeiters exploit exactly this desperation.

The World Health Organization estimates that up to 10% of medicines circulating in low- and middle-income countries may be falsified or substandard. A high-demand, high-margin product like Keytruda offers an irresistible target.

The Shadow of the Immunotherapy Revolution

Keytruda's rise as a target for counterfeiters tracks directly with the explosive growth of immunotherapy itself.

After ipilimumab became the first approved immune checkpoint inhibitor in 2011, Keytruda received FDA approval for melanoma in 2014. Its indications expanded rapidly, and its superior survival outcomes in clinical trials earned it the label of 'miracle drug.' Demand surged globally—but affordable, official access did not keep pace. In countries with weak regulatory infrastructure, patients poured their savings into informal supply chains, creating a vacuum that criminal networks rushed to fill.

As the New Delhi 2024 bust illustrates, counterfeiters use sophisticated packaging nearly indistinguishable from genuine products. Vials filled with antifungals, saline, or water are sold as premium immunotherapy. Victims typically discover the truth only after the drug has failed—when the treatment window is already closed.

Looking Ahead [Expert Analysis]

The ICIJ investigation suggests the problem is moving beyond individual harm toward a potential systemic crisis in healthcare trust.

First, the paradox of harm: counterfeit immunotherapy drugs may not cause immediate toxic side effects—antifungal agents aren't acutely lethal—but denying a cancer patient effective treatment at a critical moment amounts to a 'silent killing.' This makes harm difficult to quantify and accountability hard to assign.

Second, the regulatory gap: while counterfeit medicines have been found even in wealthy-nation hospitals, the burden falls disproportionately on countries with weak enforcement capacity. As global supply chains grow more complex, interdiction is likely to become harder.

Third, the manufacturer's dilemma: Merck applies serial numbers and holographic security features, but counterfeiting technology evolves in parallel. Some experts see blockchain-based drug traceability as a potential solution, though meaningful deployment in developing-country infrastructure is likely still years away.

Fourth, without addressing affordability, counterfeit demand will persist. Keytruda's patent is expected to expire around 2028, and biosimilar competition could eventually reduce prices—but in the interim, millions of patients will likely continue seeking the drug through unsafe informal channels.

Piya will never know for certain whether her mother's death was caused by a fake drug. That uncertainty may be the cruelest harm of all. Across the world, countless families are living inside the same uncertainty right now.